NCT02452255

Fenofibrate and Propranolol in Burn Patients

Mechanisms of Fenofibrate and Propranolol Alone or Combined in Burn Patients

• Status: Terminated
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: The University of Texas Medical Branch, Galveston · Academic / Other
• Sex: All
• Age: 80 Years
• Healthy volunteers: Not accepted

Summary

The proposed study will test the hypothesis that Propranolol, fenofibrate and fenofibrate plus propranolol have therapeutic, physiological, and metabolic effects that will improve clinical outcomes, and the long-term recovery, rehabilitation, and QOL in burned patients.

Detailed description

Determine the clinical benefits and underlying mechanisms whereby the metabolic perturbators fenofibrate and propranolol impact burn patient outcomes. The investigators hypothesize that these metabolic regulators given for one year will maintain body mass, improve muscle function by increasing protein synthesis, augment wound healing, reduce fibrosis, improve cardiovascular function, reduce systemic inflammation, restore insulin sensitivity, and decrease liver dysfunction without the risk of the hypoglycemia.

Conditions

• Burn

Interventions

Type	Name	Description
DRUG	Fenofibrate	Fenofibrate by mouth given daily throughout hospitalization for up to 12 months
DRUG	Placebo	Placebo by mouth given daily throughout hospitalization for up to 12 months
DRUG	Propranolol	Propranolol by mouth given daily throughout hospitalization for up to 12 months

Timeline

• Start date: 2015-11-01
• Primary completion: 2018-12-01
• Completion: 2019-07-12
• First posted: 2015-05-22
• Last updated: 2019-11-29

Locations

1 site across 1 country: United States